KR20200062071A - Peptide, compositions, and methods for stimulating adipogenesis - Google Patents

Abstract

Provided are: poly-L-lysine having a molecular weight of 5,000 or more and 150,000 or less, which stimulates subcutaneous adipogenesis or heals wounds; and uses thereof. A pharmaceutical or cosmetic composition according to embodiments can heal wounds by containing poly-L-lysine, which is effective for wound healing.

Description

Peptide, composition and method to stimulate fat production{PEPTIDE, COMPOSITIONS, AND METHODS FOR STIMULATING ADIPOGENESIS}

The present description relates to peptides, compositions and methods that stimulate fat production.

Recently, the demand for various products of consumers for the health and beauty of the skin has skyrocketed. Human skin becomes thinner and drier with extreme changes with age, due to thinning of the epithelial layer and degeneration of fat and connective tissue underlying the epithelial layer. Other signs of aging skin include loss of skin elasticity, elasticity and resilience. Skin on the face and neck is particularly susceptible to signs of aging. Signs of aging affecting the skin of the face and neck include, for example, wrinkles, fine wrinkles, thinned skin, sagging skin, dry skin and itching of the skin.

There are a wide variety of creams and lotions that can cosmetically improve the appearance of the skin on the face and body, and sometimes its structure. These compositions usually use retinoids, hydroxy acids and/or exfoliants that promote skin rejuvenation, increase elasticity, or otherwise cosmetically improve the skin. Many cosmetic products can increase the appearance of the skin by providing moisture and firming the skin with irritants that cause inflammation. In addition, there are known active cosmetic ingredients that require augmentation of fat production, but their potency is variable and therefore their use does not appear to be effective.

Medical procedures such as dermal injection and restorative surgery are also available to reduce signs of aging. Cosmetic surgery has recently become popular in order to aesthetically increase the appearance of the skin. In addition, stimulation of fat production acts as an important factor for the repair of wound tissues in addition to the purpose of beauty. Accordingly, what is needed is a composition and method that can stimulate fat production to improve the aging skin and/or wounds of the face and body.

The present disclosure seeks to provide pharmaceutical or cosmetic compositions capable of stimulating fat production.

The present disclosure seeks to provide methods that can stimulate fat production.

The composition according to the embodiments is poly-L-lysine having a molecular weight of 5,000 or more and 150,000 or less for stimulating subcutaneous adipogenesis or healing a wound. And pharmaceutically or cosmetically acceptable carriers.

The molecular weight of the poly-L-lysine may be 30,000 or more and 70,000 or less.

The composition may be for topical, subcutaneous or transdermal administration.

The composition may be for injection.

The composition may further include collagen, collagen derivatives, hyaluronic acid or hyaluronic acid derivatives.

The composition may be a skin cream.

A method for stimulating adiogenesis or healing a wound according to embodiments comprises administering the composition to a subject in an amount sufficient to reduce the body surface of the scar or improve the appearance of the scary body surface. Or improving the appearance of the skin, comprising administering the composition to the subject in an amount sufficient to improve the appearance of the skin in the subject's body surface, or the composition reduces, eliminates or fills wrinkles, reduces sagging skin, It may be a method of improving the surface texture of the skin, removing or reducing age spots, reducing or removing dark circles under the eyes, or administering the composition to a subject in an amount sufficient to increase the tissue volume of the body surface. .

Other details of aspects of the present invention are included in the detailed description below.

The pharmaceutical or cosmetic composition according to the embodiments can effectively stimulate fat production by including poly-L-lysine effective for stimulation of fat production. In addition, the pharmaceutical or cosmetic composition according to the embodiments can heal wounds by including poly-L-lysine effective for wound healing.

Figure 1 shows the results of observing the fat accumulation in the cells using the oil red O staining method.
2 and 3 show the results of confirming factors that increase expression by adipocyte differentiation.
Figure 4 shows the results of measuring the amount of triglycerides when treated with KSEVSK and poly-L-lysine, respectively.
Figure 5 shows the results confirming that pAKT is induced in 3T3L1 adipocytes during poly-L-lysine treatment.
Figure 6 shows the results of observing the change in the level of adipocyte differentiation when insulin and poly-L-lysine were treated respectively.
7 is an experimental result for confirming the main period in which poly-L-lysine is involved in adipocyte differentiation.
8 shows the results of observing the effect of poly-L-lysine to increase cell migration capacity.

Hereinafter, exemplary embodiments will be described in detail so that those skilled in the art can easily implement them. The embodiments may be implemented in various different forms, and are not limited to the specific embodiments described herein.

It is generally known that peptides composed of very small amino acids are effective for adipocyte differentiation. KR10-2015-0088841 also discloses that peptides consisting of 1 to 6 or 1 to 31 amino acids are effective for stimulating fat production.

However, according to the present disclosure, unlike previously known facts, poly-L-lysine within a specific molecular weight range is more effective in stimulating fat production.

Specifically, when the molecular weight of poly-L-lysine is 5,000 to 150,000, it is more effective in stimulating fat production. Furthermore, when the molecular weight of poly-L-lysine is 30,000 to 70,000, it is more effective in stimulating fat production.

In the present disclosure, poly-L-lysine may include, in addition to a polypeptide composed of only 100% L-linesin, a variant that retains its essential properties, that is, its ability to induce adiogenesis. In general, variants have very similar overall molecular weights and can be identical in many areas to poly-L-lysine. In addition to the substitution of conservative amino acids, poly-L-lysine variants are (i) substituted with one or more non-conserved amino acid residues (the substituted amino acid residues may or may not be standard amino acids and may be naturally occurring amino acids or naturally occurring amino acids). May not be amino acids) and/or (ii) conservative substitutions with one or more non-standard or non-naturally occurring amino acid residues, and/or (iii) compounds that increase the stability and/or solubility of the peptide (e.g. Fusion of a peptide with another compound, such as, for example, polyethylene glycol), and/or (iv) addition, such as, for example, an IgG Fc fusion region peptide, or a leader or secretory sequence, or a sequence that promotes purification. And fusion of the peptide with an amino acid. Methods for making such variant peptides are within the skill of those skilled in the art. For example, peptide variants containing amino acids that are charged or substituted with neutral or amino acids that have different charges can produce peptides with improved properties, such as low aggregation.

In addition, poly-L-lysine may have one or more protecting groups. The protecting group can be coupled to the C- and/or N-terminus of the peptide and/or one or more internal residues of the peptide.

Pharmaceutical and cosmetic composition

Poly-L-lysine having a molecular weight of 5,000 to 150,000 can be provided in pharmaceutical and/or cosmetic compositions with a pharmaceutically or cosmetically acceptable carrier.

Poly-L-lysine can be administered to a subject (eg, a mammal) in need of it to stimulate subcutaneous adipocyte formation or to heal a wound. The poly-L-lysine can be administered in the "in situ" form or, if desired, in the form of a salt, ester, amide, prodrug, derivative, etc. provided that the salt, ester, amide, prodrug or derivative is pharmacological It can be selected from materials that are suitable, ie effective for the method(s). Salts, esters, amides, prodrugs, and other derivatives of peptides are known to those skilled in the art of synthetic organic chemistry, and can be prepared, for example, using known standard procedures.

Poly-L-lysine can be administered to a subject (eg, a mammal) in need of it to stimulate subcutaneous adipocyte formation. The poly-L-lysine can be administered in the "in situ" form or, if desired, in the form of a salt, ester, amide, prodrug, derivative, etc. provided that the salt, ester, amide, prodrug or derivative is pharmacological It can be selected from materials that are suitable, ie effective for the method(s). Salts, esters, amides, prodrugs, and other derivatives of peptides are known to those skilled in the art of synthetic organic chemistry, and can be prepared, for example, using known standard procedures.

Poly-L-lysine may be formulated for subcutaneous, parenteral, topical, oral, nasal (or otherwise inhaled), rectal, or topical administration, such as aerosol, cream, serum and transdermal products in the form of patches. Can be. The composition may be administered in various unit dosage forms depending on the method of administration. Suitable unit dosage forms can include, but are not limited to, powders, tablets, pills, capsules, lozenges, suppositories, patches, nasal sprays, injections, implantable sustained release formulations, lipid complexes, and the like.

When poly-L-lysine is combined with a cosmetically acceptable carrier to form a cosmetic composition, a filler (for example, hyaluron filler, polymethyl methacrylate (PMMA) microspheroid and collagen filler) is additionally added. Can contain

The composition may preferably be for topical, subcutaneous, or transdermal administration.

The composition may be a composition for injection.

The composition may further include collagen (eg, cow, pig, or human collagen). Collagen may be synthetic collagen, and hyaluronic acid may be a chicken rice or a fermentation product of microorganisms.

The composition may further include an anesthetic (eg, lidocaine).

The composition may be a skin cream (eg, face cream).

The composition may be a liquid formulation in the form of a serum or toner.

The composition may be a gel-like semi-solid preparation.

Pharmaceutically acceptable carriers may be approved by federal or state government agencies or U.S. Pharmacopoeia or animal, more specifically human, or other generally recognized pharmacopeia for use on animals, more specifically humans. "Carrier" means, for example, a diluent, adjuvant, excipient, adjuvant, or vehicle administered with one or more peptides described herein.

Pharmaceutically acceptable carriers may contain, for example, one or more physiologically acceptable compounds that act to stabilize the composition or increase or decrease the absorption of poly-L-lysine. Physiologically acceptable compounds may include: for example, carbohydrates such as glucose, sucrose, or dextran, antioxidants such as ascorbic acid or glutathione, chelating agents, low molecular weight proteins, protective and absorption enhancers such as lipids , A compound that reduces the scavenging ability or hydrolysis of the peptide, or other excipients, stabilizers and/or pH control buffers.

Other physiologically acceptable compounds used in the manufacture of tablets, capsules, gel caps, etc. may include, but are not limited to, binders, diluents/fillers, disintegrants, lubricants, and suspending agents.

Excipients, optional disintegrants, binders and optional lubricants, etc. are added to the poly-L-lysine and the resulting composition can be compressed to produce an oral dosage form (eg, tablets). If necessary, the compressed product can be coated using known methods for blocking taste or dissolving or sustained release of the intestine.

Other physiologically acceptable compounds that can be formulated with poly-L-lysine can include wetting agents, emulsifying agents, dispersing agents or preservatives that are particularly useful for preventing the growth or action of microorganisms. Excipients can be used sterile and free of contaminants.

Poly-L-lysine can be incorporated topically and incorporated into formulations for cosmetic use and can be formulated as a skin cream (eg, face cream) or body lotion, wrinkle-removing cream, or as a cosmetic, sunscreen, or moisturizer Can be incorporated in.

Poly-L-lysine can also be incorporated into formulations optionally further comprising fillers, moisturizers, vitamins (eg, vitamin E), and/or colorants/dyes.

Suitable injectable cosmetic formulations may include, but are not limited to, formulations incorporating poly-L-lysine with one or more filler materials. Exemplary materials usable as injectable cosmetic wrinkle fillers include, but are not limited to, temporary (absorbable) fillers such as collagen (e.g. synthetic collagen, bovine collagen, porcine collagen, human collagen, etc.), hyaluronic acid gels, calcium hydroxide Hydroxyapatite (typically implanted in the form of a gel), or poly-L-lactic acid (PLLA), and the like. Peptides can also be incorporated into injectable cosmetic formulations containing permanent (non-absorbable) fillers. Exemplary “permanent” fillers can include, but are not limited to, polymethylmethacrylate beads (PMMA microspheres).

Poly-L-lysine can be incorporated into or administered with dermal fillers, injectables, etc.: Such injectable formulations may further include an anesthetic (eg, lidocaine or an analog thereof). Injectable formulations are substantially sterile or sterile and/or comply with regulatory agency guidelines for subcutaneous injectable fillers

Poly-L-lysine can be administered to a subject using any route known in the art, the route being, for example, by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular, or Intradermal), inhalation, transdermal application, rectal administration, vaginal administration, or oral administration. Preferred routes of administration include subcutaneous, transdermal, or topical application.

An effective amount of poly-L-lysine can be administered via topical (ie, non-systemic) administration, such as peripheral administration including, but not limited to, peripheral intramuscular, in-line, and subcutaneous administration.

Administration of poly-L-lysine can be in any convenient way, for example, by injection, intravenous and arterial stent (including elution stent), catheter, oral administration, inhalation, transdermal application, rectal administration, and the like.

Poly-L-lysine can be formulated with a pharmaceutically acceptable carrier prior to administration, eg, as described above. Pharmaceutically acceptable carriers are determined in part by the particular composition to be administered, as well as by the particular method used to administer the composition.

The dose administered in a subject should be sufficient to affect the beneficial therapeutic response (eg, increased subcutaneous adipogenesis) in the subject over time, in the context of the methods described herein. Dosage will be determined by the efficacy of the particular vehicle/delivery method employed, the site of administration, route of administration, and the condition of the subject, as well as the weight or surface area of the subject to be treated. The size of the dose will also be determined by the presence, nature, and extent of any negative side effects accompanying the administration of a specific peptide in a particular subject.

Poly-L-lysine can be administered systemically (eg, orally, or as an injection) according to standard methods well known to those skilled in the art. Peptides can be administered to the oral cavity in various forms, such as lozenges, aerosol sprays, mouthwashes, coated cotton swabs, and the like. Various oral, and sublingual formulations are also contemplated. Poly-L-lysine can be administered in a depot formulation when formulated as an injection to provide treatment over a period of time.

Poly-L-lysine can be administered topically, for example, to the skin surface, to local lesions or wounds, to surgical sites, and the like.

Poly-L-lysine can be delivered through the skin using a conventional transdermal drug delivery system, i.e., a transdermal "patch," and poly-L-lysine is typically deposited as a drug delivery device to be attached to the skin. It may be contained in the structure.

Other formulations for topical delivery include, but are not limited to, ointments, gels, sprays, fluids, and creams. The ointment can be a semi-solid preparation, typically based on petrolatum or other petroleum derivatives. As with other carriers or vehicles, the ointment base should be inert, stable, non-irritating and non-sensitizing. Creams containing the selected poly-L-lysine may typically be a viscous liquid or semi-solid emulsion, often oil-in-water or water-in-oil. Cream bases are typically water washable and contain an oil phase, an emulsifier and an aqueous phase. The specific ointment or cream base to be used is one that will be provided for optimal drug delivery, as will be appreciated by those skilled in the art.

Poly-L-lysine is a "concentrate" in a storage container prepared for dilution (eg, in a pre-determined volume), or in a soluble capsule prepared for addition to large amounts of water, alcohol, hydrogen peroxide, or other diluents. It can be provided as. For example, the peptide can be lyophilized for later reconstitution.

Poly-L-lysine can have a variety of uses. Poly-L-lysine can find use in many applications. For example, subcutaneous fat gives the skin fullness and firmness, so improving the formation of subcutaneous fat has use in plastic surgery procedures. Aging skin contains less subcutaneous fat. Thus, promoting subcutaneous fat formation by administering one or more of the poly-L-lysines described herein to a desired site can result in skin that is fuller and looks younger. This approach can replace current methods of transplanting adipocytes from other parts of the body (eg, thighs or hips), a process that often results in low success rates.

Poly-L-lysine can be administered to selectively enhance subcutaneous adipose tissue (eg, to improve subcutaneous adipose tissue without substantially increasing visceral fat and/or other adipose tissue). In response to administration of poly-L-lysine, adipocyte formation occurs in dermal fibroblasts, and volume can be added within the subcutaneous site selected in the subject.

Poly-L-lysine can be used to reduce scarring. This can be achieved by administering one or more poly-L-lysine in an amount sufficient to reduce the scar area and/or improve the appearance of the scar area. The scar may be, for example, a scar produced by burns, a scar produced by surgery, a scar produced by acne, a scar produced by biopsy, or an injury scar.

Poly-L-lysine can be used in various cosmetic processes, for example, to improve the appearance of the skin. This can be achieved by administering one or more peptides to a site of the subject in an amount sufficient to improve the appearance of the skin. Such administration may include subcutaneous administration to areas such as lips, eyelids, cheeks, forehead, chin, neck, and the like. These peptides reduce wrinkles, reduce sagging skin, improve the surface texture of the skin, reduce or eliminate wrinkles, fill, remove or reduce age spots, and/or remove dark circles under the eyes. Etc. These cosmetic applications are exemplary and not intended to be limiting.

Poly-L-lysine can be used to improve tissue volume at the site of the subject. This can be accomplished by administering one or more of the peptides described herein in an amount sufficient to increase tissue volume at the site of the subject. For example, an increase in tissue volume may include firming or augmenting breast tissue and/or firming or augmenting hip tissue or other parts of the body or face.

Poly-L-lysine can also be used to soften the skin within the subject's area. This can be achieved by administering one or more of the peptides described herein in an amount sufficient to soften the skin at the desired site. The softening may include softening the skin scarred by acne, softening the area of cellulite, softening or reducing the pregnancy line, and/or straightening wrinkles.

Poly-L-lysine can be used to mobilize stem cells into the formation of subcutaneous fat in a subject. This can be achieved by administering poly-L-lysine in an amount sufficient to mobilize the stem cells into the formation of subcutaneous fat. It has utility in, for example, various reconstructive surgical procedures.

Poly-L-lysine can be used to reconstruct tissue in subjects. Such reconstruction may include, for example, breast reconstruction (eg, after surgery to remove the tumor), or facial or limb reconstruction (eg, after an automobile accident or burn). This can be achieved by administering poly-L-lysine in an amount that increases the volume of the tissue during or after the tissue reconstruction process. Poly-L-lysine can optionally be used in combination with a tissue transplant material or other procedure that enhances the healing of skin or injured tissue.

Poly-L-lysine can be used to reduce heel pain in a subject by walking in an amount sufficient to reduce the heel pain experienced by the subject when walking.

Poly-L-lysine can be administered for the expansion of subcutaneous fat to increase thermoregulation and/or improve immune function. Subjects can be treated with poly-L-lysine to prevent disease, or to treat ongoing disease associated with increased organ fat, including but not limited to cardiovascular disease, and other obesity related diseases.

Administration in any of these methods can be local or systemic and can be by any route described herein, such as topical, subcutaneous, transdermal, oral, nasal, vaginal, and/or rectal administration. Preferably, the poly-L-lysine can be administered by subcutaneous injection. Alternatively, the poly-L-lysine may be administered topically in the form of a skin cream such as a face cream, or transdermally via a transdermal patch.

Although the above uses and methods have been described in relation to their use in humans, they are also suitable for animals, for example veterinary uses. Thus, certain preferred organisms include, but are not limited to, human, non-human primates, canines, horses, cats, pigs, ungulates, rabbits, and the like.

Hereinafter, preferred experimental examples are provided to help understanding of the present invention, but the following experimental examples are only illustrative of the present invention and the scope of the present invention is not limited to the following examples.

Cell culture and poly-L-lysine (PLL) treatment

3T3L1 adipocytes were cultured in a 37 degree, 5% CO2 environment using DEME (Dulbecco's modified Eagle's medium) containing 10% bovine serum and 1% penicillin/streptomycin. After incubation for 2 days after the cells were full, adipocyte differentiation was induced by exchanging with adipocyte differentiation medium. Adipose cell differentiation was induced by sequentially exchanging three types of media. For the first time in 10% fetal bovine serum (FBS) DMEM, 0.5 uM 3-isobutyl-1-methylxanthine (IBMX), 0.25 uM dexamethasone, 5 ug/ml insulin Cultured for 2 days. After that, the cells were cultured for 2 days by exchanging with 10% FBS and DMEM containing 1 ug/ml insulin, and then cultured in DMEM containing 10% FBS for 4 days. Poly-L-lysine was added to each adipocyte differentiation medium to treat the cells.

Oil Red O Dye

The cells were washed with PBS and then fixed by treatment with 3.5% formaldehyde for 10 minutes. After washing with PBS, a 1.5% Oil red O solution was treated with 60% isopropanol for 1 hour. After washing with PBS, it was observed after drying.

result

Fat cell differentiation effect

From the experimental results, it was found that Poly-L-lysine having a molecular weight of 5,000 or more has an effect of enhancing adipocyte differentiation. During the differentiation induction process of 3T3L1 adipocytes into adipocytes, adipocyte differentiation medium was treated with poly-L-lysine (PLL) having different molecular weights (MW) by concentration. Adipose cell differentiation was compared by observing the amount of fat accumulation in the cells using the Oil Red O staining method. As illustrated in FIG. 1, the effect of increasing the amount of fat accumulation in the cells was not observed by treatment with MW 1,000-5,000 poly-L-lysine, whereas the increase of the amount of fat accumulation in the cells was dependent on the concentration of PLL in PLL of MW 5,000 or more Did.

Next, as factors that increase expression by adipocyte differentiation, the levels of PPARg, C/EBPa, adiponectin, and FABP4 were confirmed. 2 and 3, in the experimental group treated with MW 1,000-5,000 poly-L-lysine, the level of these factors was similar to the experimental group not treated with poly-L-lysine, but high molecular weight poly- It was confirmed that the level of these factors increased in the L-lysine treatment group. In addition, a better tendency of differentiation promoting effect was observed in the MW 30,000-70,000 poly-L-lysine treatment group. Through these results, it was confirmed that adipocyte differentiation was increased by poly-L-lysine treatment of MW 5,000 or more and 150,000 or less.

Effect of activating insulin signaling system

Compared to KSEVSK, which has been reported to have a differentiation-enhancing effect, the differentiation-enhancing effect of poly-L-lysine was compared. For this experiment, adipocyte differentiation was induced using a medium in which MW 30,000-70,000 PLL or KSEVSK was added to adipocyte differentiation-inducing medium.

As shown in Figure 4, while the increase in triglyceride accumulation by KSEVSK treatment was not observed, in the poly-L-lysine treatment group, it was confirmed that the intracellular triglyceride accumulation increased. Next, differentiation was induced by adding poly-L-lysine or KSEVSK to the adipocyte differentiation-inducing medium without insulin. In the case of subtracting insulin from the components of the adipocyte differentiation-inducing medium and using medium in which KSEVSK was added instead of insulin, intracellular triglyceride accumulation hardly occurred. On the other hand, in the case of using media in which adipocyte differentiation-inducing medium component was subtracted from insulin and added poly-L-lysine, it was observed that the amount of triglyceride accumulation increased, and it was confirmed that adipocyte differentiation was induced.

Since adipocyte differentiation progressed when PLL was added to the adipocyte-free adipocyte differentiation induction medium, it was confirmed whether poly-L-lysine can stimulate the insulin signaling system like insulin. 3T3L1 adipocytes were used to determine the level of pAKT belonging to the insulin signaling system. As illustrated in FIG. 5, it was confirmed that it stimulates the insulin signaling system by confirming that pAKT is induced by poly-L-lysine treatment, although it is lower than the level of pAKT induction by insulin. However, no further increase in pAKT levels was observed when insulin and poly-L-lysine were treated together. In order to confirm whether the effect of promoting adipocyte differentiation by poly-L-lysine is due to stimulation of the insulin signaling system, adipocyte differentiation according to insulin concentration and the treatment group of poly-L-lysine was compared. In the process of inducing differentiation of adipocytes, adipocyte differentiation was induced by not adding insulin during the differentiation day 0-2, insulin 5ug/ml, day 3-4, insulin 1ug/ml, and day 5-8.

Unlike the existing adipocyte differentiation method, adipocyte differentiation level changes were observed by continuously processing various insulin concentrations during the adipocyte differentiation induction process (day0-day8). As shown in Figure 6, except for the group that was continuously treated with insulin 500 ug/ml, increasing the amount of triglyceride in the cell by continuous high concentration (5 ug/ml ~ 100 ug/ml) insulin treatment I could confirm. However, through the failure to increase the level of triglyceride accumulation by poly-L-lysine, it was confirmed that there are other pathways and functions other than stimulation of insulin signaling system in the mechanism of promoting adipocyte differentiation by poly-L-lysine.

During the adipocyte differentiation process, in order to confirm the main period during which poly-L-lysine is involved in adipocyte differentiation, the amount of triglyceride accumulation in the cells was determined by varying the PLL treatment period. As shown in FIG. 7, when poly-L-lysine was treated for 2-8 days, the effect of adipogenesis was hardly observed, whereas poly-L-lysine treatment for day 0-2 resulted in intracellular triglyceride. Through the increase in the accumulation amount, it was confirmed that day 0-2 is the main action period of poly-L-lysine.

Wound healing ability test

Cell migration assay was performed in human skin keratinocyte cell line HaCaT (Human Keratinocyte) cells. Mobility was measured using IncuCyte® Bioscience. Mobility was measured using MW 30,000-70,000 poly-L-lysine and the results are shown in FIG. 8. It can be seen from the results of FIG. 8 that cell migration potency was increased at concentrations of 50, 150, and 500 ng/ml of poly-L-lysine. It can be seen that in the 25 hour treatment condition, about 10% increased compared to the control. In addition, it was found from the results of the 12-hour treatment conditions that the concentrations of poly-L-lysine showed higher cell migration capacity than those of 500 ng/ml at 50 ng/ml and 150 ng/ml. On the other hand, it was confirmed that inhibition of cell migration was observed at a concentration of 1500 ng/ml or more. From this, it can be confirmed that poly-L-lysine not only has an effect of promoting fat differentiation, but also has a wound healing potency.

Although the experimental examples have been described above, the scope of rights is not limited thereby. The embodied form can be implemented in various ways within the scope of the detailed description of the invention and the accompanying drawings, and it is natural that this also belongs to the scope of rights.

Claims (7)

Poly-L-lysine having a molecular weight of 5,000 or more and 150,000 or less for stimulating subcutaneous adipogenesis or healing wounds; And
A composition comprising a pharmaceutically or cosmetically acceptable carrier. According to claim 1,
The poly-L-lysine has a molecular weight of 30,000 or more and 70,000 or less. According to claim 1,
The composition is for topical, subcutaneous or transdermal administration. According to claim 1,
The composition is for injection. According to claim 1,
The composition further comprises collagen, collagen derivatives, hyaluronic acid or hyaluronic acid derivatives. According to claim 1,
The composition is a skin cream composition. The method according to any one of claims 1 to 6,
Reducing the scar, comprising administering to the subject an amount sufficient to reduce the body surface of the scar or improve the appearance of the scared body surface,
Improving the appearance of the skin, comprising administering the composition to the subject in an amount sufficient to improve the appearance of the skin in the subject's body surface, or
The composition reduces wrinkles, removes or fills, reduces sagging skin, improves the skin's surface texture, removes or reduces age spots, or reduces or eliminates dark circles under the eyes,
A method comprising administering said composition to a subject in an amount sufficient to increase the tissue volume of the body surface.

Images